Independent Community Pharmacists’ Experience in Offering Pharmacogenetic Testing
Open Access
- 1 July 2021
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 14, 877-886
Abstract
Objective: This study assessed pharmacist experiences with delivering pharmacogenetic (PGx) testing in independent community pharmacies. Methods: We conducted a cluster randomized trial of independent community pharmacies in North Carolina randomized to provide either PGx testing as a standalone service or integrated into medication therapy management (MTM) services. Surveys and pharmacist data about the delivery of PGx testing were collected. Semi-structured interviews were also conducted. Results: A total of 36 pharmacists participated in the study from 22 pharmacies. Sixteen pharmacists completed the pre-study and post-study surveys, and four pharmacists completed the semi-structured interviews. Thirty-one percent (11/36) of pharmacists had had some education in personalized medicine or PGx prior to the study. The only outcome that differed by study arm was the use of educational resources, with significantly higher utilization in the PGx testing only arm (p=0.007). Overall, compared to the pre-study assessment, pharmacists’ knowledge about PGx significantly improved post-study (p=0.018). In the post-study survey, almost all pharmacists indicated that they felt qualified/able to provide PGx testing at their pharmacy. While 75% of pharmacists indicated that they may continue to provide PGx testing at their pharmacy after the study, the major concerns were lack of reimbursement for PGx counseling and consultation given the necessary time required. Conclusion: Our findings demonstrated a positive experience with delivering PGx testing in the community pharmacy setting with little difference in pharmacists’ experiences in providing PGx testing with or without MTM. Pharmacists were confident in their ability to provide PGx testing and were interested in continuing to offer testing, though sustained delivery may be challenged by lack of prescribing provider engagement and reimbursement.Keywords
This publication has 52 references indexed in Scilit:
- Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reportingClinical Pharmacology & Therapeutics, 2015
- Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic TestingClinical Pharmacology & Therapeutics, 2014
- Emerging Roles for Pharmacists in Clinical Implementation of PharmacogenomicsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Implementation of personalized medicine services in community pharmacies: Perceptions of independent community pharmacistsJournal of the American Pharmacists Association, 2014
- Point-of-care testing for infectious diseases: Opportunities, barriers, and considerations in community pharmacyJournal of the American Pharmacists Association, 2014
- Implementation of a pharmacogenomics service in a community pharmacyJournal of the American Pharmacists Association, 2014
- Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics ServicePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide SurveyClinical Pharmacology & Therapeutics, 2012
- Knowledge, Attitudes and Education of Pharmacists Regarding Pharmacogenetic TestingPersonalized Medicine, 2011
- Integrating pharmacogenomics into pharmacy practice via medication therapy managementJournal of the American Pharmacists Association, 2011